Vascular Response to Isoproterenol and β2 Adrenergic Receptor Polymorphisms

This study has been completed.

First Received: September 12, 2005 Last Updated: October 28, 2008 History of Changes

Sponsor:	Hadassah Medical Organization
Information provided by:	Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00226551

Purpose

Single nucleotide polymorphisms at codon 46 and 79 of the gene encoding for the ß2 adrenergic receptor (ß2AR) modify its pharmacological properties and may alter the response to ß2AR agonists. The goal of the present study was to evaluate the role played by the Arg16Gly and Gln27Glu polymorphisms on isoproterenol induced relaxation of internal mammary arteries segments ex-vivo.

Internal mammary leftover segments were collected from 96 patients undergoing coronary artery bypass graft operation. Four rings that were prepared from each specimen were allowed to reach equilibrium with physiological Krebs solution prior to precontraction with U46619. Using the organ bath technique, cumulative dose response curve of isoproterenol was constructed and mean EC50 calculated for each patient.

Condition	Intervention
Coronary Disease	Drug: Isoproterenol

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study
Official Title:	ß2 Adrenergic Receptor Polymorphisms and Vasodilation of Internal Mammary Artery Induced by Isoproterenol

Resource links provided by NLM:

MedlinePlus related topics: Coronary Artery Disease

Drug Information available for: Isoproterenol hydrochloride Isoproterenol sulfate Isoproterenol

U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:

Mean Ec50% in response to rising concentration of isoproterenol

Estimated Enrollment:	100
Study Start Date:	August 1999

Eligibility

Ages Eligible for Study:	20 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

patients scheduled to undergo coronary artery bypass graft operation

Exclusion Criteria:

Chronic treatment with corticosteroids

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00226551

Locations

Israel
Hadassah Medical Organization
Jerusalem, Israel

Sponsors and Collaborators

Hadassah Medical Organization

Investigators

Principal Investigator:

Yoseph Caraco, MD

Hadassah Medical Organization

More Information

No publications provided by Hadassah Medical Organization

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):

Khalaila JM, Elami A, Caraco Y. Interaction between beta2 adrenergic receptor polymorphisms determines the extent of isoproterenol-induced vasodilatation ex vivo. Pharmacogenet Genomics. 2007 Oct;17(10):803-11.

Study ID Numbers:	yc19558-HMO-CTIL
Study First Received:	September 12, 2005
Last Updated:	October 28, 2008
ClinicalTrials.gov Identifier:	NCT00226551 History of Changes
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:

Respiratory System Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Cardiotonic Agents
Myocardial Ischemia
Physiological Effects of Drugs
Arteriosclerosis
Adrenergic Agonists
Therapeutic Uses
Cardiovascular Diseases
Arterial Occlusive Diseases
Heart Diseases

Adrenergic beta-Agonists
Sympathomimetics
Vascular Diseases
Anti-Asthmatic Agents
Cardiovascular Agents
Protective Agents
Pharmacologic Actions
Isoproterenol
Coronary Disease
Autonomic Agents
Peripheral Nervous System Agents
Bronchodilator Agents
Coronary Artery Disease

ClinicalTrials.gov processed this record on November 09, 2009